We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (3178)4/24/2018 1:11:12 PM
From: tuck  Read Replies (1) | Respond to of 3202
believe that Epa is not dead
Which remaining combos(s) are of interest?

Edit: This P1 with a surviving vaccine looks interesting, and reads out in the next few months.

Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer

Partial rationale: Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients

TIA & Cheers, Tuck

To: Miljenko Zuanic who wrote (3178)4/24/2018 2:45:27 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 3202
So you bought after the disaster, and believe Epa still lives? Interesting, hope it works for you.

I haven't owned shares for ages. I had no interest in a "universal lever on the immune response", believing that a non-specific lean on Tregs and dendritic cells wouldn't deliver. There are many agents that just gently nudge the balance between effectors and Tregs, still don't understand why IDO became the realm to bet on.

Disaster in I/O space doesn't hold water, my view. Why IDO's issues float into TLR9, sting or GITR (etc.) space escapes me. Wishing you luck, as any success would lead to rather pronounced profit.

off topic.... forced selling in VKTX?